Latest posts tagged with #BrainMets on Bluesky
Ther Adv Med Oncol: Real‑world pyrotinib beyond progression vs rechallenge in HER2+ mBC (incl. brain mets): PFS2 ~7.2 vs 6.3 mo (NS); OS 31.6 vs 21.0 mo (trend). CNS subgroup also benefited. Read: 【🔗https://buff.ly/xsK4lFw 】 #BreastCancer #HER2 #BrainMets #Oncology
Analysis of 346 BCBM cases from the GEICAM RegistEM registry reveals faster CNS progression and poorer survival in TNBC and HER2+ subtypes, with major differences between de novo vs subsequent brain metastases.
🔗 buff.ly/74yHwuH
#BreastCancer #BrainMets #HER2 #TNBC #RealWorldEvidence
Dr. Veronica Chiang shares updates on three #clinicaltrials she is leading that target brain metastases. #brainmets
medicine.yale.edu/news-article...
Thrilled to be part of the upcoming Brain & Spine Metastases Conference! Join me and colleagues to explore the latest in brain and spine mets. Use code Ahmed for a discounted rate! Register here: www.gotoper.com/brainspinemets #BMC25 #BrainMets #SpineMets
💡 Clinical Tip: In MBC (esp. HER2+ & TNBC), discuss brain metastasis risk proactively — patient-centered dialogue is key while awaiting trial evidence.
#BreastCancer #BrainMets #MetastaticBC #OncoTwitter #MedicalWatch
👉 Recently published in Clinical Cancer Research: A population-level real-world analysis and single-center validation of melanoma brain metastasis epidemiology following dual-agent immunotherapy 🔗 doi.org/10.1158/1078... #EANOessentials #NeuroOncology #BrainMetastases #brainMets #medsky
CIMARa has 4 goals:
1) Establish an infrastructure to enhance discovery & development of #brainmetstherapies
2) Provide a network of experts to advance & implement clinical trials for patients with #brainmets
3) Harmonize study end-points
4) Develop a common forum for discussion
Hello! Formally introducing CIMARa. Led by CareyAnders
(@dukemets.bsky.social) and @HTawbi_MD
(@mdanderson.bsky.social), we are physicians, scientists, non-profits & advocates who share the goal of improving outcomes for patients with #brainmets through awareness & coordination of research.
Happening now! Join us to learn from this great group of speakers. #CNS #pediatricbraintumor #braintumor #glioma #gbm #neurosurgery #brainmets #brainmetastasis
Fine-tune your strategies for using #HER2 targeting tx in HER2+ #MBC with and without #BrainMets: Get expert insight in this video from @PeerView & @graspcancer.bsky.social featuring Sara A. Hurvitz, MD, FACP, and colleagues. bit.ly/4fk0wD5
Why are our findings significant?
Routine ERBB2 testing in EAC patients could guide early HER2-targeted therapy - and can identify high-risk patients for brain metastasis.
JAK2 alterations may help stratify patients for immunotherapy.
Thanks for reading!
#brainmets #oncology
Really excited to share our lab's first manuscript! I cant be more proud of our team, especially @nora-mae.bsky.social who diligently worked on this project.
It will be a long thread but I promise it's worth it!
#Oncology #BrainMets
.@drsgraff.bsky.social provides a clear overview of treatments for HER2+ MBC with a lot of discussion around those living with #brainmets. ADCs are now indicated for patients with active CNS disease #OncoAlertColloquium #BreastCancer
The late, great Laura Greco had 8 brain surgeries because of #BrainMets. Lung Cancer spreads to the brain more often than any other cancer.
We deserve better.
#LMD #lcsm
For Emma, losing her licence after a #LungCancer diagnosis with #BrainMets felt like losing her independence.
70% of #ALK+ pts get 🧠 mets, yet many don't get clear guidance on driving.
That’s why our DVLA Advisory Panel created this @pifonline.bsky.social certified guide #LCSM
📌 shorturl.at/k20oo
…or develop ways to deliver non-CNS-penetrant drugs to the central nervous system.
🔑 #OncSky #MedSky
We MUST include people w/ #brainmets, & as appropriate active untreated brain mets, in #Oncology #clinicaltrials. Preventing/treating CNS mets will be the final frontier in #bcsm.
/END
#OncSky #bcsm
👉Remember this, esp in isolated #brainmets or isolated CNS progression
👉Determine if we can reliably detect same alterations in CSF (or innovate to make 🧠 biopsy ⬇️ invasive)
👉Prioritize CNS penetrant agents w/ 👌 safety for #drugdevelopment
/3
www.nature.com/articles/s41...
#MedSky #OncSky
NEW & IMPORTANT Genomic profiling performed on 822 #breastcancer #brainmets (BCBM) + thousands of local breast tumors & non-brain mets (unpaired).
🔑 HRD & #ImmunoOnc-predictive biomarkers are significantly more common in BCBM.
🔑 There were some diffs by #bcsm subtype.
/1
Now at #esmobreast24 it’s #BrainMets. Should we routinely screen? I know most MBC patients would say 👍🏻. Dr Emilie Le Rhun provides @myESMO guidelines. Brain mets are more common in HER2+ & TNBC, but can also occur in ER+. Brain mets also tend to occur sooner in TNBC.
via @NYTimes
watching a fascinating story on @60Minutes about Dr Ali Razai and the use of focused ultrasound to open the blood brain barrier to improved delivery of drugs to people with Alzheimer’s- this could be so impactful in #BrainMets...
Tucatinib (Tukysa) in the HER2 Climb trial really changed the paradigm by allowing people with active #BrainMets to enroll. This is so important due to the high incidence of brain mets in HER2+ #MetastaticBreastCancer @cure_today #bcsm
Dr @AyalAizer should we be screening people with MBC for #brainmets routinely? There is trial in progress (will look later and add link to head later) #bcsm
what about drugs other than tucatinib for #brainmets in HER2+ MBC? Lots of encouraging data, and ongoing trials. #bcsm
Tucatinib is tyrosine kinase inhibitor that is super exciting, especially for those with active #brainmets. #bcsm
very interesting @UCSFBreastForum talk by Dr Claire Robertson, a materials scientist, on brain mets. Different subtypes of #breastcancer metastasize to different areas of the brain (white/yellow are more frequent sites) #brainmets #metastatic #bcsm
.@cure_magazine HER2CLIMB was THE story of 2019, given the response in people with #brainmets. Everyone with brain mets who did NOT get tucatinib had progression, but ~ 25% who got tucatinib had not progressed at 1 year! And it also lowered the risk of dying by 1 year!!!! #BCSM
#SABCS20 can we make any conclusions at this time whether tucatinib or netatinib should be used in people with #brainmets? This panel says can't really say since no head-to-head comparison, need to look at side effects profile and what may be more tolerable to each person. #bcsm
BUT ASCENT shows very little improvement of PFS in people with #brainmets treated with sacituzimab vs physician's treatment of choice. #sabcs20 #bcsm
#SABCS20 what about sacituzimab in #brainmets? 2/10 of the original patients with brain mets are still responding, with shrinkage of their brain mets. #bcsm
